Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 432, Issue 1, 2013, Pages 123-128

  Choi, Ha Na ^a   Jin, Hyeon Ok ^a   Kim, Jae Hee ^a   Hong, Sung Eun ^a   Kim, Hyun Ah ^b   Kim, Eun Kyu ^b   Lee, Jin Kyung ^b   Park, In Chul ^a   Noh, Woo Chul ^b  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Breast cancer; Glucose deprivation; Mcl 1; S6K1; Survivin

Indexed keywords

ENZYME INHIBITOR; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; PF 4708671; PROTEIN MCL 1; S6 KINASE; S6 KINASE 1; SMALL INTERFERING RNA; SORAFENIB; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL STRAIN MCF 7; CELL STRESS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MCF-7 CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOR SERINE-THREONINE KINASES;

EID: 84875366769     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.074     Document Type: Article

References (22)

1. Thompson C.B., Bauer D.E., Lum J.J., Hatzivassiliou G., Zong W.X., Zhao F., Ditsworth D., Buzzai M., Lindsten T. How do cancer cells acquire the fuel needed to support cell growth?. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:357-362.
2. Garber K. Energy deregulation: licensing tumors to grow. Science 2006, 312:1158-1159.
3. Zhu Z., Jiang W., McGinley J.N., Price J.M., Gao B., Thompson H.J. Effects of dietary energy restriction on gene regulation in mammary epithelial cells. Cancer Res. 2007, 67:12018-12025.
4. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
5. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
6. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
7. Bärlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M.L., Torhorst J., Haas P., Bucher C., Sauter G., Kallioniemi O.P., Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 2000, 92:1252-1259.
8. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
9. Sinclair C.S., Rowley M., Naderi A., Couch F.J. The 17q23 amplicon and breast cancer. Breast Cancer Res. Treat. 2003, 78:313-322.
10. van der Hage J.A., van den Broek L.J., Legrand C., Clahsen P.C., Bosch C.J., Robanus-Maandag E.C., van de Velde C.J., van de Vijver M.J. Overexpression of p70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br. J. Cancer 2004, 90:1543-1550.
11. Yamnik R.L., Digilova A., Davis D.C., Brodt Z.N., Murphy C.J., Holz M.K. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J. Biol. Chem. 2009, 284:6361-6369.
12. Pearce L.R., Alton G.R., Richter D.T., Kath J.C., Lingardo L., Chapman J., Hwang C., Alessi D.R. Characterization of PF4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 2010, 431:245-255.
13. Ahmad T., Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 2004, 10:6388S-6392S.
14. Gollob J.A., Wilhelm S., Carter C., Kelley S.L. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 2006, 33:392-406.
15. Rahmani M., Davis E.M., Bauer C., Dent P., Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 2005, 280:35217-35227.
16. Kim Y.S., Jin H.O., Seo S.K., Woo S.H., Choe T.B., An S., Hong S.I., Lee S.J., Lee K.H., Park I.C. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem. Pharmacol. 2011, 82:216-226.
17. Mills J.R., Hippo Y., Robert F., Chen S.M., Malina A., Lin C.J., Trojahn U., Wendel H.G., Charest A., Bronson R.T., Kogan S.C., Nadon R., Housman D.E., Lowe S.W., Pelletier J. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. USA 2008, 105:10853-10858.
18. Vaira V., Lee C.W., Goel H.L., Bosari S., Languino L.R., Altieri D.C. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007, 26:2678-2684.
19. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaría G., Kim H., Zapata J.M., Marusawa H., Chamorro M., Reed J.C. The bioenergetics signature of cancer: a marker of tumor progression. Cancer Res. 2002, 62:6674-6681.
20. Hsu P., Sabatini D. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
21. Kim E.K., Kim H.A., Koh J.S., Kim M.S., Kim K.I., Lee J.I., Moon N.M., Ko E., Noh W.C. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res. Treat. 2011, 126:93-99.
22. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.